How do you prioritize semaglutide versus intensive lifestyle therapy when addressing residual cardiovascular risk in a patient with established ASCVD, obesity, and no diabetes?

In a patient with established ASCVD and a BMI of 27 or greater, I discuss semaglutide therapy, in addition to lifestyle therapy, as an important and evidence-based therapy to reduce their risk of recurrent ASCVD events. This would be a shared decision with the patient based on their preferences, cov...